Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease
- 23 May 2005
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 21 (7), 981-987
- https://doi.org/10.1185/030079905x49644
Abstract
Background/Aims: Previous studies have hinted at possible associations between anemia and progression of renal disease. The study objective was to determine whether treatment with erythropoiesis-stimulating proteins (ESPs) can curb the rate of decline in renal function in pre-dialysis patients with chronic kidney disease (CKD). Methods: Observational, before/after analysis using electronic medical records from the Veterans Administration (VA). Included patients had at least two measurements of serum creatinine levels before and after ESP treatment initiation. The Cockcroft–Gault formula was used to derive estimates of glomerular filtration rate (GFR). Rate of renal function decline prior to and following initiation of therapy were compared. Results: One hundred and twenty two patients with renal impairment levels of Stage 3 (moderate) or Stage 4 (severe) at ESP treatment initiation were identified. Over 80% of patients initiated therapy with either Grade 1 or Grade 2 anemia. The rate of renal function decline was calculated as the slope of the least-squares linear regression line of the inverse serum creatinine over time during the pre-treatment initiation and post-treatment initiation time periods. Overall, patients experienced a slowing in the rate of renal function decline after treatment was initiated (mean pre-treatment initiation rate of –0.094 dL/mg/yr versus mean post-treatment initiation rate of –0.057 dL/mg/yr). Conclusion: Renal function declined at a slower rate following ESP initiation. Results are consistent with prior studies indicating delayed dialysis initiation in patients treated with ESPs. Analyses were limited by the observational study design and lack of information regarding some potential confounders. Longer-term, prospective trials are needed to determine whether ESPs slow progression of renal disease and the potential magnitude of such an effect.Keywords
This publication has 11 references indexed in Scilit:
- The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous ironNephrology Dialysis Transplantation, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesThe New England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2001
- Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patientsNephrology Dialysis Transplantation, 2001
- IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000American Journal of Kidney Diseases, 2001
- Chemotherapy-Induced Anemia in Adults: Incidence and TreatmentJNCI Journal of the National Cancer Institute, 1999
- Angiotensin II receptor antagonists and treatment of hypertension and renal diseaseCurrent Opinion in Nephrology and Hypertension, 1998
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyThe New England Journal of Medicine, 1993
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976